This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by DeBois, W. J Articles by Isom, O W. Search for Related Content PubMed PubMed Citation Articles by DeBois, W. J Articles by Isom, O W. Social Bookmarking                   What's this?

Diagnosis and treatment of heparin-induced thrombocytopenia

New York-Presbyterian Hospital, New York Weill Cornell Center, New York, USA, wdebois{at}nyp.org

Junli Liu

New York-Presbyterian Hospital, New York Weill Cornell Center, New York, USA

Leonard Y Lee

New York-Presbyterian Hospital, New York Weill Cornell Center, New York, USA

Leonard N Girardi

New York-Presbyterian Hospital, New York Weill Cornell Center, New York, USA

Charles Mack

New York-Presbyterian Hospital, New York Weill Cornell Center, New York, USA

Anthony Tortolani

New York-Presbyterian Hospital, New York Weill Cornell Center, New York, USA

Karl H Krieger

New York-Presbyterian Hospital, New York Weill Cornell Center, New York, USA

O Wayne Isom

New York-Presbyterian Hospital, New York Weill Cornell Center, New York, USA

Heparin-induced thrombocytopenia (HIT) is a major side effect secondary to the administration of heparin. This syndrome is serious and potentially life threatening. This response is the result of antibodies formed against the platelet factor 4 (PF4)/heparin complex. The incidence of this immune-mediated syndrome has been estimated to be 1-3% of all patients receiving heparin therapy. The occurrence of HIT in patients requiring full anticoagulation for cardiopulmonary bypass (CPB), therefore, presents a serious challenge to the cardiac surgery team. The diagnosis of HIT should be based on both clinical and laboratory evidence. While functional assays, platelet aggregation tests, and the serotonin release assay can be used to support the diagnosis, the negative predictive value of these tests is generally less than 50%. In contrast, although non-functional antibody detection assays are more sensitive, they have a low specificity. HIT can be treated in several ways, including cessation of all heparin and giving an alternative thrombin inhibitor, platelet inhibition followed by heparin infusion, and the use of low molecular weight heparins. In this presentation, the pathology and current diagnostic tests, as well as the successful management of patients with HIT undergoing CPB at New York Presbyterian Hospital, are reviewed.

Perfusion, Vol. 18, No. 1, 47-53 (2003)
DOI: 10.1191/0267659103pf637oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?